The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ... activation and mediated clearance of diseased hepatocytes and HCC ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement SPRING HOUSE, Pa. /PRNewswire/ -- Third Arc Bio Inc., a clinical stage ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Highlights Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT ... agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and ...

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...

Eating a version of the high-carbohydrate, low-fat ketogenic diet for six months led to an anti-inflammatory shift in immune ...

today announced the activation of its first clinical trial site at The University of Texas MD Anderson Cancer Center for its Phase 1 study evaluating BTM-3566 in relapsed/refractory mature B-cell ...